Charles Schwab Investment Management Inc. Decreases Stock Holdings in USANA Health Sciences, Inc. (NYSE:USNA)

Charles Schwab Investment Management Inc. reduced its holdings in USANA Health Sciences, Inc. (NYSE:USNA) by 21.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 140,856 shares of the company’s stock after selling 38,166 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.74% of USANA Health Sciences worth $5,055,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in USNA. Barclays PLC raised its holdings in USANA Health Sciences by 111.9% during the 3rd quarter. Barclays PLC now owns 27,737 shares of the company’s stock valued at $1,052,000 after buying an additional 14,647 shares during the period. Rhumbline Advisers raised its stake in shares of USANA Health Sciences by 39.8% in the fourth quarter. Rhumbline Advisers now owns 49,390 shares of the company’s stock valued at $1,773,000 after acquiring an additional 14,068 shares during the period. Principal Financial Group Inc. lifted its holdings in shares of USANA Health Sciences by 2.8% in the 4th quarter. Principal Financial Group Inc. now owns 53,603 shares of the company’s stock worth $1,924,000 after acquiring an additional 1,480 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of USANA Health Sciences by 4.5% during the 3rd quarter. Geode Capital Management LLC now owns 297,120 shares of the company’s stock worth $11,269,000 after purchasing an additional 12,898 shares during the period. Finally, State Street Corp grew its holdings in USANA Health Sciences by 0.6% during the 3rd quarter. State Street Corp now owns 435,164 shares of the company’s stock valued at $16,501,000 after purchasing an additional 2,782 shares during the last quarter. 54.25% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CEO Jim Brown sold 5,000 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $29.47, for a total transaction of $147,350.00. Following the transaction, the chief executive officer now directly owns 15,716 shares in the company, valued at approximately $463,150.52. This trade represents a 24.14 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider David Mulham Mulham sold 3,234 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $32.98, for a total transaction of $106,657.32. Following the completion of the transaction, the insider now directly owns 12,775 shares of the company’s stock, valued at $421,319.50. This trade represents a 20.20 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 15,920 shares of company stock worth $500,285. Company insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on USNA shares. DA Davidson decreased their price objective on shares of USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating for the company in a research note on Thursday, February 27th. StockNews.com cut USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, February 14th. Finally, Sidoti lowered USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 18th.

USANA Health Sciences Price Performance

USANA Health Sciences stock opened at $26.21 on Wednesday. The stock has a market cap of $495.50 million, a price-to-earnings ratio of 9.26, a price-to-earnings-growth ratio of 0.93 and a beta of 0.98. The firm has a 50-day moving average of $31.52 and a two-hundred day moving average of $35.25. USANA Health Sciences, Inc. has a 1 year low of $26.19 and a 1 year high of $49.78.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, February 25th. The company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.15. The company had revenue of $213.61 million for the quarter, compared to analysts’ expectations of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. Research analysts expect that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.

USANA Health Sciences Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.